NDATOPICALSOLUTION
Approved
Jun 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
6/8 — Strong
JUBLIA (efinaconazole) by Bausch + Lomb. Approved for azole antifungal [epc]. First approved in 2014.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JUBLIA (efinaconazole) is a topical azole antifungal solution approved in 2014 for treating fungal nail infections. It works by inhibiting fungal cell membrane synthesis through cytochrome P450 inhibition. The product is currently at peak lifecycle stage with sustained commercial performance.
$94MPart D
PeakStable
8.6 years to LOEMature product with solid recurring revenue base; commercial team maintains steady patient base with limited growth opportunity.
Mechanism of Action
Pharmacologic Class:
Azole Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis
Started Nov 2017
97 enrolled
Mild to Moderate Onychomycosis Due to Dermatophyte
Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis
Started Aug 2016
62 enrolled
Onychomycosis
Career Relevance
JUBLIA represents a stable career opportunity within a mature, profitable dermatology asset with solid reimbursement ($94M annual Part D spending). Roles emphasize maintaining market share, managing payer relationships, and optimizing patient access rather than launching or rapid growth.
Worked on JUBLIA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.